NATURALISTA CAMPANO
ISSN: 1827-7160
Volume 28 Issue 1, 2024

Investigating the Therapeutic Effects of Gold Nanoparticles in Neurological Diseases

Mohit Kotnala[1], Shaik Kareemulla[2], Avinash Kumar Vivekanand Mishra[3], Murali Krishna Kandukuri[4], Syed Ahmed Iizhar[5], Sagar Narendra Ande[6], RLC Sasidhar[7*]

[1]Science Teacher, Bloom Charter Education, Ain Al Fayedah School-6021 Abu Dhabi United Arab Emirates.
[2]Associate Professo, Associate Professo, Pharmacy Practice, M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed University), Mullana-Ambala, Haryana, India. Pin code: 133207
[3]Vice President, Biokart India Pvt Ltd (Biokart Genomics Lab), 5m-612, Balaji Complex, B.Channasandra Main Rd, OMBR Layout, Bangalore - 560043, Karnataka, India
[4]Associate Professor, Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee
[5]Associate Professor, Dept of pharamacetuics, Sultan UL Uloom college of Pharmacy, Mount pleasant, Banjara Hills, Hyderabad Telangana 500034
[6]Associate Professor, Dr. Rajendra Gode Institute of Pharmacy, University Mardi Road, Ghatkheda, Amravati 444602 Maharashtra India
[7*]Professor, Department of Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur-522019

Corresponding: Dr. RLC Sasidhar
Email id: rlcsasidhar@gmail.com
Designation and Affiliation: Professor, Department of Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur-522019

Abstract: Gold nanoparticles (GNPs) are emerging as a promising tool in the treatment of neurological diseases due to their unique physicochemical properties and multifunctionality. This review explores the therapeutic applications of GNPs in addressing the complex pathologies of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke and traumatic brain injury. GNPs exhibit anti-inflammatory and antioxidant effects, protect neurons, and enhance drug delivery to the central nervous system (CNS). Advances in GNP design, including next-generation and multifunctional nanoparticles, are discussed, highlighting their potential to improve targeting and efficacy. Personalized nanomedicine approaches offer tailored treatments based on individual patient profiles, enhancing therapeutic outcomes. Additionally, the integration of GNPs with conventional therapies can produce synergistic effects, amplifying treatment efficacy. This review underscores the potential of GNPs to revolutionize the management of neurological diseases, paving the way for precision medicine and improved patient care.

Keywords: Gold nanoparticles, neurological diseases, Alzheimer's disease, Parkinson's disease, multifunctional nanoparticles.

1. Introduction

Neurological diseases encompass a wide range of disorders affecting the brain, spinal cord, and nerves. These conditions can lead to debilitating symptoms, including motor dysfunction, cognitive decline, and sensory impairments [1]. Common neurological diseases include Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. According to the World Health Organization (WHO), neurological disorders affect hundreds of millions of people globally, with Alzheimer's and other dementias affecting approximately 50 million people worldwide [2]. Parkinson's disease affects about 10 million people, and multiple sclerosis affects an estimated 2.8 million people globally. The prevalence of these diseases is expected to rise due to the aging population and increasing life expectancy. Neurological diseases have a profound impact on patients, their families, and healthcare systems [3]. Patients often experience a significant decline in quality of life, loss of independence, and psychological distress. Caregivers also face substantial emotional, physical, and financial burdens. These diseases lead to extensive healthcare utilization, including frequent hospitalizations, long-term care, and medication needs [4]. The economic burden is substantial, with costs attributed to direct medical expenses, indirect costs such as lost productivity, and the long-term care required for chronic conditions. For

example, in the United States alone, the annual cost of dementia care exceeds $300 billion, and this figure is projected to increase dramatically in the coming decades [5]. Nanomedicine is an interdisciplinary field that applies nanotechnology principles to medical and healthcare applications [6]. It involves the use of nanoscale materials, typically ranging from 1 to 100 nanometers, to diagnose, treat, and prevent diseases. The small size of nanoparticles allows them to interact with biological systems at the molecular level, providing unique opportunities for targeted therapy, improved drug delivery, and enhanced diagnostic techniques [7]. Nanomedicine encompasses a wide range of applications, including drug delivery systems, imaging agents, diagnostic devices, and regenerative medicine.

Gold Nanoparticles: Properties and Synthesis

A. Physical and Chemical Properties

Size and Shape: Gold nanoparticles (GNPs) can be synthesized in a variety of sizes and shapes, ranging from 1 to 100 nanometers in diameter. The size and shape of GNPs significantly influence their physical, chemical, and biological properties. Common shapes include spheres, rods, cubes, and stars [8]. The surface area-to-volume ratio, which increases with decreasing size, plays a crucial role in the interaction of GNPs with biological systems. Smaller nanoparticles have a higher surface area, enhancing their reactivity and ability to be functionalized with therapeutic or diagnostic molecules [9].

Surface Chemistry: The surface chemistry of GNPs is pivotal for their functionality in biomedical applications. GNPs possess a high surface energy, making them highly reactive and suitable for surface modification[10]. Functionalization of GNPs can be achieved through various chemical groups, such as thiols, amines, and carboxyl groups, which attach to the gold surface. This allows for the attachment of drugs, targeting ligands, and other biomolecules, enabling the customization of GNPs for specific therapeutic or diagnostic purposes[11].

Optical Properties: GNPs exhibit unique optical properties due to surface plasmon resonance (SPR), where conduction electrons on the nanoparticle surface oscillate in resonance with incident light. This results in strong absorption and scattering of light, which can be tuned by altering the size, shape, and aggregation state of the nanoparticles [12]. These optical properties make GNPs excellent candidates for applications in imaging, diagnostics, and photothermal therapy, where they can be used to enhance contrast or generate localized heat to destroy diseased cells [13].

B. Methods of Synthesis

Chemical Reduction: Chemical reduction is one of the most common methods for synthesizing GNPs. It involves the reduction of gold salts, such as chloroauric acid, using reducing agents like sodium citrate or borohydride [14]. This method allows precise control over the size and shape of the nanoparticles by adjusting parameters such as the concentration of reactants, temperature, and reaction time. Chemical reduction is advantageous due to its simplicity, scalability, and the production of high-purity nanoparticles[15].

Biological Synthesis: Biological synthesis of GNPs, also known as green synthesis, utilizes biological entities such as plants, bacteria, fungi, and algae to reduce gold salts into nanoparticles[16]. This eco-friendly approach avoids the use of toxic chemicals and harsh conditions, making it more sustainable and biocompatible. Biological molecules, such as proteins and polysaccharides, act as both reducing and stabilizing agents, leading to the formation of biocompatible GNPs with potential applications in biomedicine[17].

Physical Methods: Physical methods for GNP synthesis include techniques like laser ablation, photochemical reduction, and vapor deposition. These methods typically involve the physical disruption of bulk gold into nanoparticles[18]. For example, laser ablation uses a high-energy laser to irradiate a gold target submerged in a liquid, producing nanoparticles. While these methods can produce high-purity GNPs with unique properties, they often require specialized equipment and can be less scalable compared to chemical and biological methods[19].

C. Functionalization of GNPs

Surface Modification Techniques: Surface modification is essential for enhancing the functionality and stability of GNPs. Techniques include the adsorption or covalent attachment of molecules onto the nanoparticle surface[20]. Common modifications involve attaching polyethylene glycol (PEG) to improve biocompatibility and circulation time, or coating with silica to enhance stability and prevent aggregation. These modifications can tailor GNPs for specific biomedical applications, such as drug delivery and imaging[21].

Targeting Ligands: Functionalization with targeting ligands, such as antibodies, peptides, or small molecules, allows GNPs to specifically bind to target cells or tissues[22]. This targeting capability is crucial for applications in precision medicine, where GNPs can deliver therapeutic agents directly to diseased cells while minimizing off-target effects. For instance, targeting ligands can direct GNPs to cancer cells or areas of inflammation in neurological diseases, enhancing the efficacy of treatments[23].

Biocompatibility Considerations: Ensuring biocompatibility is critical for the clinical application of GNPs. Biocompatible coatings, such as PEG or biopolymers, can reduce immune recognition and prolong circulation time in the bloodstream[24]. Additionally, it is important to assess the potential toxicity of GNPs, which can vary depending on size, shape, surface charge, and concentration. Rigorous in vitro and in vivo studies are required to evaluate the safety and biocompatibility of GNPs, ensuring they do not induce adverse immune responses or toxicity[25].



Figure 1: The Mechanisms of Action of Curcumin in the Brain

Mechanisms of Action of Gold Nanoparticles in Neurological Diseases

A. Anti-inflammatory Effects

Mechanisms of Inflammation in Neurological Diseases: Inflammation plays a pivotal role in the pathogenesis of various neurological diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis[26]. Chronic inflammation in the central nervous system (CNS) can result from the activation of microglia and astrocytes, leading to the release of pro-inflammatory cytokines, chemokines, and reactive oxygen species (ROS). This inflammatory milieu exacerbates neuronal damage and contributes to disease progression[27].

Role of GNPs in Modulating Inflammatory Pathways: Gold nanoparticles (GNPs) have shown potential in modulating inflammatory pathways. GNPs can inhibit the activation of microglia and astrocytes, thereby reducing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6[28]. Additionally, GNPs can interfere with the NF-κB signaling pathway, a key regulator of inflammation, further dampening the inflammatory response. By attenuating inflammation, GNPs may protect neurons from inflammatory damage and slow the progression of neurological diseases[29].

B. Antioxidant Properties

Oxidative Stress in Neurological Diseases: Oxidative stress, characterized by an imbalance between the production of ROS and the body's antioxidant defenses, is a common feature of many neurological diseases.

Excessive ROS can damage cellular components, including lipids, proteins, and DNA, leading to neuronal injury and death. Oxidative stress is implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[30].

GNPs as Free Radical Scavengers: GNPs possess intrinsic antioxidant properties that enable them to scavenge free radicals and reduce oxidative stress. GNPs can neutralize ROS directly or upregulate endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase. By mitigating oxidative stress, GNPs can protect neurons from oxidative damage and enhance cellular survival in neurological diseases[31,5].

C. Neuroprotection

Mechanisms of Neurodegeneration: Neurodegeneration involves a cascade of pathological processes, including protein misfolding, mitochondrial dysfunction, excitotoxicity, and synaptic loss. These processes contribute to the progressive loss of neurons and cognitive and motor deficits observed in neurological diseases[32,3].

Protective Effects of GNPs on Neurons: GNPs have demonstrated neuroprotective effects in various models of neurological diseases. They can inhibit apoptosis (programmed cell death) by modulating apoptotic pathways and reducing the activation of caspases, which are key enzymes in the apoptotic process[22]. GNPs can also protect mitochondria from dysfunction, preserving their role in energy production and cellular metabolism. Additionally, GNPs can promote neuronal survival and differentiation, supporting the regeneration and repair of damaged neural tissue[12].

D. Drug Delivery Systems

GNPs as Carriers for Neurotherapeutic Drugs: One of the significant challenges in treating neurological diseases is delivering therapeutic agents across the blood-brain barrier (BBB). GNPs can be engineered as carriers for neurotherapeutic drugs, enhancing their delivery to the CNS[17]. By conjugating drugs to the surface of GNPs, it is possible to increase the solubility, stability, and bioavailability of these drugs, facilitating their transport across the BBB[33].

Targeted Delivery to the Central Nervous System (CNS): Targeted delivery to the CNS is crucial for effective therapy with minimal side effects. GNPs can be functionalized with targeting ligands, such as peptides, antibodies, or aptamers, which bind specifically to receptors on the surface of brain endothelial cells or neurons[34]. This targeted approach ensures that GNPs accumulate in the desired brain regions, enhancing the therapeutic efficacy and reducing off-target effects[6]. Additionally, GNPs can be designed to release their therapeutic payloads in a controlled manner, providing sustained drug delivery and improving treatment outcomes for neurological diseases[3,7].

Table 1: Neuroprotective and Anti-inflammatory Effects of Gold Nanoparticles in Alzheimer's Disease

Biological Model	**Pathways**	**Targets/Mechanisms**	**References**
Cell Culture Models	Inhibition of NF-κB signaling pathway	Reduction of pro-inflammatory cytokine production	[12]
	Modulation of microglial activation	Suppression of neuroinflammation	[4]
	Prevention of amyloid-beta aggregation	Inhibition of amyloid-beta-induced neurotoxicity	[2]
Animal Models	Regulation of oxidative stress	Scavenging of reactive oxygen species (ROS)	[19]
	Enhancement of antioxidant defenses	Upregulation of antioxidant enzyme expression	[3]
	Preservation of synaptic integrity	Protection against synaptic dysfunction and loss	[17]
	Promotion of neurogenesis	Stimulation of neuronal growth and regeneration	[5]
	Maintenance of blood-brain barrier	Preservation of BBB integrity, reducing neuroinflammation	[10]

Therapeutic Applications of Gold Nanoparticles in Specific Neurological Diseases

A. Alzheimer's Disease

Pathophysiology: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein[11]. This leads to synaptic dysfunction, neuronal death, and cognitive decline. Chronic inflammation, oxidative stress, and mitochondrial dysfunction are also key features of AD pathology[35].

Therapeutic Potential of GNPs: Gold nanoparticles (GNPs) offer several therapeutic potentials for AD. They can inhibit the aggregation of amyloid-beta peptides, reducing plaque formation. GNPs can also serve as carriers for anti-amyloid drugs, enhancing their delivery and efficacy[36]. Additionally, GNPs' antioxidant properties help mitigate oxidative stress, protecting neurons from damage. The anti-inflammatory effects of GNPs can reduce neuroinflammation, further supporting neuronal health. Functionalization of GNPs with targeting ligands enables them to cross the blood-brain barrier (BBB) and accumulate in the brain, ensuring precise delivery to affected areas[37].

B. Parkinson's Disease

Pathophysiology: Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremors, rigidity, and bradykinesia. The presence of Lewy bodies, composed of aggregated alpha-synuclein protein, is a hallmark of PD. Oxidative stress and mitochondrial dysfunction are critical contributors to neuronal death in PD[38].

GNP-based Interventions: GNPs can intervene in PD by preventing the aggregation of alpha-synuclein, thus reducing Lewy body formation. Their antioxidant properties can counteract oxidative stress, protecting dopaminergic neurons[39]. GNPs can also be functionalized to deliver neuroprotective drugs or genes specifically to the substantia nigra, enhancing therapeutic efficacy. Additionally, GNPs' ability to modulate inflammation can help alleviate neuroinflammation associated with PD. These multifaceted roles make GNPs a promising tool for addressing the complex pathology of PD[40].

C. Multiple Sclerosis

Pathophysiology: Multiple sclerosis (MS) is an autoimmune disease characterized by the demyelination of neurons in the CNS, leading to disrupted nerve signal transmission. Inflammation and immune cell infiltration into the CNS are central to MS pathology, resulting in neuronal damage and neurological deficits[41].

Role of GNPs in Treatment: GNPs can play a significant role in treating MS by modulating the immune response. Their anti-inflammatory properties can reduce the activation of immune cells and the release of pro-inflammatory cytokines[42]. GNPs can also serve as carriers for immunomodulatory drugs, enhancing their delivery to the CNS and improving therapeutic outcomes. Additionally, GNPs can promote remyelination and protect neurons from oxidative stress, supporting neuronal repair and functional recovery. The ability to target specific cellular pathways and deliver drugs precisely makes GNPs a valuable asset in MS therapy[43].

D. Stroke and Traumatic Brain Injury

Pathophysiology: Stroke and traumatic brain injury (TBI) result in acute neuronal damage due to disrupted blood flow or mechanical injury, leading to cell death, inflammation, and secondary injury processes. Oxidative stress, excitotoxicity, and BBB disruption are common pathological features[44].

GNPs in Neuroprotection and Recovery: GNPs can provide neuroprotection in stroke and TBI by scavenging free radicals and reducing oxidative stress, thereby minimizing neuronal damage. Their anti-inflammatory effects can mitigate secondary injury by suppressing the inflammatory response[45]. GNPs can also promote neurogenesis and angiogenesis, facilitating tissue repair and recovery. As carriers, GNPs can deliver neuroprotective drugs or genes to the injured brain regions, enhancing therapeutic effectiveness. Moreover, their ability to cross the BBB ensures that therapeutic agents reach the site of injury, supporting recovery and functional improvement[46].

Future Perspectives and Directions

A. Advancements in GNP Design

Next-Generation GNPs: The future of gold nanoparticles (GNPs) in nanomedicine lies in the development of next-generation GNPs. These will feature improved biocompatibility, enhanced targeting capabilities, and optimized therapeutic efficacy[47]. Innovations may include the creation of ultrasmall GNPs that can easily

penetrate tissues and cellular barriers or the design of GNPs with tunable optical and electronic properties to better interact with biological systems. Advances in synthesis methods will also allow for more precise control over GNP size, shape, and surface chemistry, enabling the production of nanoparticles tailored to specific medical applications[48].

Multifunctional Nanoparticles: Multifunctional GNPs represent a significant advancement, as they can perform multiple roles simultaneously. For instance, a single GNP could be engineered to deliver drugs, provide imaging contrast, and target specific cells or tissues[49]. This multifunctionality can enhance the efficiency and effectiveness of treatments by combining therapeutic and diagnostic functions (theranostics) into a single platform. Such GNPs could carry therapeutic agents while also allowing real-time monitoring of treatment progress through imaging, thus enabling more dynamic and responsive medical interventions[50].

B. Personalized Nanomedicine

Tailoring GNPs for Individual Patients: Personalized nanomedicine involves customizing GNPs to meet the unique needs of individual patients. This could be based on genetic profiles, disease biomarkers, or specific patient characteristics. Tailoring GNPs could involve modifying their size, surface properties, or functional groups to optimize their interaction with a patient's unique biological environment. Personalized GNPs could improve the efficacy and safety of treatments by ensuring that therapies are precisely targeted and appropriate for each patient's condition[51,4,7].

Precision Medicine Approaches: Precision medicine aims to develop treatments that are specifically designed for subgroups of patients based on their genetic, environmental, and lifestyle factors[52,53]. In the context of GNPs, precision medicine could involve using nanoparticles to deliver drugs that target specific molecular pathways involved in a patient's disease[54,55]. By leveraging genomic and proteomic data, clinicians can design GNP-based therapies that target the root causes of diseases, offering a higher likelihood of treatment success and reducing the risk of side effects[56-60].

C. Integration with Other Therapies

Combining GNPs with Conventional Treatments: Integrating GNPs with conventional treatments, such as chemotherapy, radiation therapy, or surgery, can enhance therapeutic outcomes[61,62]. GNPs can be used to deliver conventional drugs more effectively, reducing the required dosages and minimizing side effects[563-65]. For example, GNPs can enhance the delivery of chemotherapeutic agents directly to cancer cells, improving the efficacy of treatment while sparing healthy tissues[66,67]. Similarly, GNPs can be used to enhance the effects of radiation therapy by acting as radiosensitizers, making cancer cells more susceptible to radiation damage[68,69].

Synergistic Effects and Combination Therapies: The combination of GNPs with other therapies can produce synergistic effects, where the combined treatment is more effective than the sum of its parts[70,71]. For instance, GNPs can be used in combination with immunotherapy to stimulate the immune system more effectively against cancer[72,73]. They can also be combined with targeted therapies to deliver drugs that inhibit specific cancer pathways while simultaneously addressing other aspects of the disease. By integrating GNPs with various therapeutic modalities, it is possible to develop more comprehensive and potent treatment strategies[74-80].

2. Conclusion

Gold nanoparticles (GNPs) present a transformative potential in the treatment of neurological diseases due to their unique properties, such as biocompatibility, ease of functionalization, and exceptional optical characteristics. These nanoparticles can modulate inflammatory and oxidative pathways, offering neuroprotection and enhancing the delivery of neurotherapeutic drugs across the blood-brain barrier. Advances in GNP design, including the development of next-generation multifunctional nanoparticles, promise to improve targeting and efficacy. Personalized nanomedicine approaches will tailor GNP-based treatments to individual patient profiles, optimizing therapeutic outcomes. Furthermore, integrating GNPs with conventional therapies could yield synergistic effects, enhancing the overall effectiveness of treatment regimens. As research progresses, GNPs are set to become a cornerstone in the innovative landscape of neurological disease management, providing new avenues for precision medicine and improving patient care. The continued exploration of their multifaceted applications underscores the exciting potential of GNPs to revolutionize the future of medical treatments.

3. References

1. Vashist, P. Manickam, A. D. Raymond, A. Y. Arias, N. Kolishetti, A. Vashist, E. Arias, and M. Nair, "Recent Advances in Nanotherapeutics for Neurological Disorders," ACS Appl. Bio Mater., vol. 6, pp. 2614–2621, 2023. doi: 10.1021/acsabm.3c00254.
2. M. Aili, K. Zhou, J. Zhan, H. Zheng, and F. Luo, "Anti-inflammatory role of gold nanoparticles in the prevention and treatment of Alzheimer's disease," J. Mater. Chem. B, vol. 11, pp. 8605–8621, 2023. doi: 10.1039/D3TB01023F.
3. J. Xue, T. Liu, Y. Liu, Y. Jiang, V. D. D. Seshadri, S. K. Mohan, and L. Ling, "Neuroprotective effect of biosynthesized gold nanoparticles synthesized from root extract of Paeonia moutan against Parkinson disease—In vitro & In vivo model," J. Photochem. Photobiol. B, vol. 200, p. 111635, 2019.
4. S. Salatin, M. Farhoudi, A. Farjami, S. Maleki Dizaj, S. Sharifi, and S. Shahi, "Nanoparticle Formulations of Antioxidants for the Management of Oxidative Stress in Stroke: A Review," Biomedicines, vol. 11, p. 3010, 2023. doi: 10.3390/biomedicines11113010.
5. J. Milan, K. Niemczyk, and M. Kus-Liskiewicz, "Treasure on the Earth—Gold Nanoparticles and Their Biomedical Applications," Materials, vol. 15, p. 3355, 2022. doi: 10.3390/ma15093355.
6. A. Bansal, V. Kumar, J. Karimi, A. P. Singh, and S. Kumar, "Role of gold nanoparticles in advanced biomedical applications," Nanoscale Adv., vol. 2, pp. 3764–3787, 2020. doi: 10.1039/D0NA00472C.
7. H. A. Nguyen and P. Falagan-Lotsch, "Mechanistic Insights into the Biological Effects of Engineered Nanomaterials: A Focus on Gold Nanoparticles," Int. J. Mol. Sci., vol. 24, p. 4109, 2023. doi: 10.3390/ijms24044109.
8. Hammami, N. M. Alabdallah, A. A. Jomaa, and M. Kamoun, "Gold nanoparticles: Synthesis properties and applications," J. King Saud. Univ. Sci., vol. 33, p. 101560, 2021. doi: 10.1016/j.jksus.2021.101560.
9. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.
10. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.
11. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.
12. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.
13. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.
14. Bano, A. Dawood, S. F. Rida, A. Malik, M. Alkholief, H. Ahmad, M. A. Khan, Z. Ahmad, and O. Bazighifan, "Enhancing catalytic activity of gold nanoparticles in a standard redox reaction by investigating the impact of AuNPs size, temperature and reductant concentrations," Sci. Rep., vol. 13, p. 12359, 2023. doi: 10.1038/s41598-023-38234-2.
15. N. R. S. Sibuyi, K. L. Moabelo, A. O. Fadaka, S. Meyer, M. O. Onani, A. M. Madiehe, and M. Meyer, "Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review," Nanoscale Res. Lett., vol. 16, p. 174, 2021. doi: 10.1186/s11671-021-03632-w.
16. M. Kus-Liskiewicz, P. Fickers, and I. Ben Tahar, "Biocompatibility and Cytotoxicity of Gold Nanoparticles: Recent Advances in Methodologies and Regulations," Int. J. Mol. Sci., vol. 22, p. 10952, 2021. doi: 10.3390/ijms222010952.
17. J. Zhang, L. Mou, and X. Jiang, "Surface chemistry of gold nanoparticles for health-related applications," Chem. Sci., vol. 11, pp. 923–936, 2020. doi: 10.1039/C9SC06497D.
18. H. Huang, R. Liu, J. Yang, J. Dai, S. Fan, J. Pi, Y. Wei, and X. Guo, "Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy," Pharmaceutics, vol. 15, p. 1868, 2023. doi: 10.3390/pharmaceutics15071868.
19. M. Khongkow, T. Yata, S. Boonrungsiman, U. R. Ruktanonchai, D. Graham, and K. Namdee, "Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood-brain barrier penetration," Sci. Rep., vol. 9, p. 8278, 2019. doi: 10.1038/s41598-019-44569-6.
20. Zhang, F. Kiessling, T. Lammers, and R. M. Pallares, "Clinical translation of gold nanoparticles," Drug Deliv. Transl. Res., vol. 13, pp. 378–385, 2023. doi: 10.1007/s13346-022-01232-4.
21. P. Talarska, M. Boruczkowski, and J. Zurawski, "Current Knowledge of Silver and Gold Nanoparticles in Laboratory Research-Application, Toxicity, Cellular Uptake," Nanomaterials, vol. 11, p. 2454, 2021. doi: 10.3390/nano11092454.

22. O. Kumar and D. K. Lim, "Gold-Polymer Nanocomposites for Future Therapeutic and Tissue Engineering Applications," Pharmaceutics, vol. 14, p. 70, 2022. doi: 10.3390/pharmaceutics14010070.
23. K. Koushki, S. K. Shahbaz, M. Keshavarz, E. E. Bezsonov, T. Sathyapalan, and A. Sahebkar, "Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders," Biomolecules, vol. 11, p. 1289, 2021. doi: 10.3390/biom11091289.
24. P. P. P. Kumar and R. Mahajan, "Gold Polymer Nanomaterials: A Promising Approach for Enhanced Biomolecular Imaging," Nanotheranostics, vol. 8, pp. 64–89, 2024. doi: 10.7150/ntno.89087.
25. J. C. Porras, M. Bernuz, J. Marfa, A. Pallares-Rusinol, M. Marti, and M. I. Pividori, "Comparative Study of Gold and Carbon Nanoparticles in Nucleic Acid Lateral Flow Assay," Nanomaterials, vol. 11, p. 741, 2021. doi: 10.3390/nano11030741.
26. Mahor, P. P. Singh, P. Bharadwaj, N. Sharma, S. Yadav, J. M. Rosenholm, and K. K. Bansal, "Carbon-Based Nanomaterials for Delivery of Biologicals and Therapeutics: A Cutting-Edge Technology," C., vol. 7, p. 19, 2021. doi: 10.3390/c7010019.
27. X. Yuan, X. Zhang, L. Sun, Y. Wei, and X. Wei, "Cellular Toxicity and Immunological Effects of Carbon-based Nanomaterials," Part. Fibre Toxicol., vol. 16, p. 18, 2019. doi: 10.1186/s12989-019-0299-z.
28. B. Begines, T. Ortiz, M. Perez-Aranda, G. Martinez, M. Merinero, F. Arguelles-Arias, and A. Alcudia, "Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects," Nanomaterials, vol. 10, p. 1403, 2020. doi: 10.3390/nano10071403.
29. Raman, S. Mahmood, A. R. Hilles, M. N. Javed, M. Azmana, and K. A. S. Al-Japairai, "Polymeric Nanoparticles for Brain Drug Delivery—A Review," Curr. Drug Metab., vol. 21, pp. 649–660, 2020. doi: 10.2174/1389200221666200508074348.
30. N. M. Martínez, J. Hernández, and J. Morales, "Nanoparticles for the potential treatment of Alzheimer's disease: A physiopathological approach," Nanotechnol. Rev 12, p. 20220548, 2023. doi: 10.1515/ntrev-2022-0548.
31. Ohta, E. Kikuchi, A. Ishijima, T. Azuma, I. Sakuma, and T. Ito, "Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood-brain barrier opening," Sci. Rep., vol. 10, p. 18220, 2020. doi: 10.1038/s41598-020-75253-9.
32. M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, and R. Langer, "Engineering precision nanoparticles for drug delivery," Nat. Rev. Drug Discov., vol. 20, pp. 101–124, 2021. doi: 10.1038/s41573-020-0090-8.
33. R. Abbasi, G. Shineh, M. Mobaraki, S. Doughty, and L. Tayebi, "Structural parameters of nanoparticles affecting their toxicity for biomedical applications: A review," J. Nanopart Res., vol. 25, p. 43, 2023. doi: 10.1007/s11051-023-05690-w.
34. E. Ferrari, "Gold Nanoparticle-Based Plasmonic Biosensors," Biosensors, vol. 13, p. 411, 2023. doi: 10.3390/bios13030411.
35. Reznickova, N. Slavikova, Z. Kolska, K. Kolarova, T. Belinova, M. Hubalek Kalbacova, M. Cieslar, and V. Svorcik, "PEGylated gold nanoparticles: Stability, cytotoxicity and antibacterial activity," Colloids Surf. A Physicochem. Eng. Asp., vol. 560, pp. 26–34, 2019. doi: 10.1016/j.colsurfa.2018.09.083.
36. L. Del Amo, A. Cano, M. Ettcheto, E. Souto, M. Espina, A. Camins, M. L. García, and E. Sánchez-López, "Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease," Appl. Sci., vol. 11, p. 4305, 2021. doi: 10.3390/app11094305.
37. Sartaj, Z. Qamar, S. Md, N. A. Alhakamy, S. Baboota, and J. Ali, "An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurological Disorders and Brain Tumor," Front. Bioeng. Biotechnol., vol. 10, p. 788128.
38. Dharmendra Bhati et al., "FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.749.
39. K. J. Mangala et al., "NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE COMPOUNDS," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.553.
40. Rohit Kumar Trivedi et al., "REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE DIRECTIONS," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.521.
41. H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, "EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND

BIOIMAGING IN CLINICAL DIAGNOSTICS," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.457.
42. M. shama, "CRISPR-Cas9 gene editing in pharmaceuticals : Current applications and future prospects," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1655.
43. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, "Advancements in peptide-based therapeutics: Design, synthesis and clinical applications," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1415.
44. M. Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," NeuroQuantology, vol. 20, no. 11, pp. 1258, 2022.
45. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
46. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.
47. A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.
48. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
49. P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.
50. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.
51. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.
52. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.
53. C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.
54. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.
55. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.
56. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.
57. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.
58. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.
59. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.
60. Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.
61. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.
62. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.
63. K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.
64. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.

65. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.
66. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.
67. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.
68. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.
69. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.
70. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.
71. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.
72. P. Bhatt et al., "Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (Echinochloa frumentacea) Grains Starch," Stärke/Starch, May 2024, doi: https://doi.org/10.1002/star.202300285.
73. Kumar et al., "Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study," Journal of bioactive and compatible polymers, May 2024, doi: https://doi.org/10.1177/08839115241249143.
74. X. Liu, J. Q. Wang, C. R. Ashby Jr., L. Zeng, Y. F. Fan, and Z. S. Chen, "Gold nanoparticles: Synthesis, physiochemical properties and therapeutic applications in cancer," Drug Discov. Today, vol. 26, pp. 1284–1292, 2021. doi: 10.1016/j.drudis.2021.01.030.
75. Sarfraz and I. Khan, "Plasmonic Gold Nanoparticles (AuNPs): Properties, Synthesis and their Advanced Energy, Environmental and Biomedical Applications," Chem. Asian J., vol. 16, pp. 720–742, 2021. doi: 10.1002/asia.202001202.
76. E. Dreaden, L. A. Austin, M. A. Mackey, and M. A. El-Sayed, "Size matters: Gold nanoparticles in targeted cancer drug delivery," Ther. Deliv., vol. 3, pp. 457–478, 2012. doi: 10.4155/tde.12.21.
77. Okoampah, Y. Mao, S. Yang, S. Sun, and C. Zhou, "Gold nanoparticles-biomembrane interactions: From fundamental to simulation," Colloids Surf. B Biointerfaces, vol. 196, p. 111312, 2020. doi: 10.1016/j.colsurfb.2020.111312.
78. V. A. Mulens-Arias, A. Balfourier, A. Nicolas-Boluda, F. Carn, and F. Gazeau, "Endocytosis-driven gold nanoparticle fractal rearrangement in cells and its influence on photothermal conversion," Nanoscale, vol. 12, pp. 21832–21849, 2020. doi: 10.1039/D0NR05886F.
79. Liu and Q. Peng, "Protein-gold nanoparticle interactions and their possible impact on biomedical applications," Acta Biomater., vol. 55, pp. 13–27, 2017. doi: 10.1016/j.actbio.2017.03.055.
80. Graczyk, R. Pawlowska, D. Jedrzejczyk, and A. Chworos, "Gold Nanoparticles in Conjunction with Nucleic Acids as a Modern Molecular System for Cellular Delivery," Molecules, vol. 25, p. 204, 2020. doi: 10.3390/molecules25010204.